David Drutz - Jan 25, 2022 Form 4/A - Amendment Insider Report for Altimmune, Inc. (ALT)

Role: Director
Signature: /s/ Kent Tapper, as Attorney-in-Fact
Stock symbol: ALT
Transactions as of: Jan 25, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 2/16/2022, 08:10 PM
Date Of Original Report: Jan 26, 2022
Previous filing: Dec 15, 2021
Next filing: May 25, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	ALT	Common Stock, par value $0.0001						17.8K	Jan 25, 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALT	Stock Options (option to buy)	Award		+139			139	May 4, 2017	Common Stock, par value $0.0001	139	$2.40	Direct	F1, F3
transaction	ALT	Stock Options (option to buy)	Award		+139			139	May 4, 2017	Common Stock, par value $0.0001	139	$17.70	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person holds a stock option granted on May 4, 2017, which is exercisable for 139 shares of common stock with an exercise price of $2.40 per share and an expiration date of December 31, 2022 (the "2022 Stock Option"). The 2022 Stock Option was previously reported as covering 4,178 shares at an exercise price of $0.08 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On January 26, 2022, the reporting person mistakenly filed a Form 4 reporting the exercise of the 2022 Stock Option for 70 shares of common stock. Such exercise did not occur. As of January 25, 2022, the reporting person owned only 17,812 shares of common stock and there were 139 shares of common stock unexercised and underlying the 2022 Stock Option.
F2	The reporting person holds a stock option granted on May 4, 2017 for 139 shares of common stock with an exercise price of $17.7 per share and an expiration date of December 31, 2023 (the "2023 Stock Option"). The 2023 Stock Option was previously reported as covering 4,177 shares at an exercise price of $0.59 per share, but was adjusted to reflect a one-for-thirty reverse stock split that occurred on September 13, 2018. On May 4, 2017, the reporting person mistakenly filed a Form 4 reporting that the 2023 Stock Option had an expiration date of December 31, 2022. The 2023 Stock Option has an expiration date of December 31, 2023.
F3	Pursuant to the terms of the Agreement and Plan of Merger, dated as of January 18, 2017, as amended on March 29, 2017, the Issuer assumed all outstanding options to purchase shares of Altimmune, Inc. capital stock on a 0.749106:1 basis upon closing of the merger.